Development
e-therapeutics plc
ETXPF
OTC PK
| 07/31/2023 | 04/30/2023 | 01/31/2023 | 10/31/2022 | 07/31/2022 | |
|---|---|---|---|---|---|
| Net Income | -1.63% | 5.35% | 8.46% | -30.59% | -113.14% |
| Total Depreciation and Amortization | 18.25% | 47.65% | 117.94% | 182.68% | 347.50% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -253.20% | -131.28% | -27.98% | 35.93% | 59.47% |
| Change in Net Operating Assets | 205.02% | 580.88% | -80.10% | -164.30% | -273.24% |
| Cash from Operations | 0.27% | 6.26% | 7.50% | -30.73% | -101.71% |
| Capital Expenditure | 84.30% | 65.55% | 41.38% | -10.07% | -106.26% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -87.15% | 382.39% | 246.24% | 225.50% | 186.35% |
| Cash from Investing | -87.23% | 368.56% | 244.04% | 222.87% | 182.79% |
| Total Debt Issued | -- | -- | -- | 0.00% | -- |
| Total Debt Repaid | -362.31% | -281.54% | -200.77% | -240.52% | -465.22% |
| Issuance of Common Stock | 63,952.38% | 23.96% | -37.99% | -68.94% | -99.90% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 1,530.67% | -4.86% | -50.42% | -73.58% | -96.84% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 157.39% | 1,823.92% | 265.05% | -17.59% | -136.25% |